Sontra Medical Completes 1-For-10 Reverse Stock Split

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Sontra Medical Completes 1-For-10 Reverse Stock Split
    FRANKLIN, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONTD) today announced it has completed a 1-for-10
reverse stock split of the Company's issued and outstanding common stock.
The reverse stock split was effective with respect to shareholders of
record at 5:00 p.m., eastern time, on August 10, 2006. As a result of the
reverse stock split, each ten shares of issued and outstanding common stock
were combined and were reclassified into one share of common stock and the
total number of shares outstanding was reduced from approximately
27,207,995 shares to approximately 2,720,799 shares. No fractional shares
were issued in connection with the reverse stock split. Shareholders who
are entitled to fractional shares will receive cash in lieu of fractional
shares. The exercise or conversion price, as well as the number of shares
of common stock that can be issued upon exercise or conversion of the
Company's outstanding stock options, warrants and shares of Series A
Preferred Stock, will be proportionately adjusted to reflect the reverse
stock split. The number of shares reserved for issuance under the Company's
equity compensation plans will also be reduced proportionately.
    As of the opening of the Nasdaq Capital Market on August 11, 2006, the
Company's common stock will begin trading at the split-adjusted level. For
a period of 20-trading days, the Company's common stock will trade on a
post- split basis under the trading symbol "SONTD". After this 20-trading
day period, the Company's common stock will resume trading under the symbol
"SONT".
    The Board of Directors approved the reverse stock split to help the
Company regain compliance with the Nasdaq Capital Market's $1 minimum bid
price continued listing requirement.
    About Sontra Medical Corporation (http://www.sontra.com)
    Sontra Medical Corporation is a technology leader in transdermal
science and is developing a non-invasive, continuous transdermal glucose
monitor ("CTGM") for principal use in the Intensive Care Market. Through
its platform technology, the SonoPrep(R) Permeation System, combined with
technical competencies in transdermal drug formulation, analysis, delivery
systems and biosensors, the Company is creating a new paradigm in
transdermal drug delivery and diagnosis. The CTGM and other company
products are being developed for several billion dollar market
opportunities, all utilizing skin permeation, chemistry and biosensor
technology developed by the Company. In addition, the Company is developing
products for transdermal delivery of large molecule drugs and vaccines.
    This press release contains forward-looking statement. Statements that
are not historical facts, including statements about our beliefs and
expectations, are forward-looking statements and include statements
regarding our planned strategic initiatives and our ability to maintain a
listing on Nasdaq. Such statements are based on our current expectations
and are subject to a number of factors and uncertainties, which could cause
actual results to differ materially from those described in the
forward-looking statements. Such factors and uncertainties include, but are
not limited to, that the Company will not be successful in its attempt for
continued listing, and risks related to our planned strategic initiatives,
including that such initiatives may not occur as planned or that they do
not result in continued listing. Forward- looking statements speak only as
of the date they are made, and we undertake no duty or obligation to update
any forward-looking statements in light of new information or future
events, unless required by law. For detailed information about factors that
could cause actual results to differ materially from those described in the
forward-looking statements, please refer to Sontra's filings with the
Securities and Exchange Commission, including Sontra's most recent
Quarterly Report on Form 10-QSB. We do not undertake any obligation to
update forward-looking statements made by us.
    SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks
or registered trademarks of their respective owners.
    Investor Relations Contact:
    Harry G. Mitchell, CFO
    508-530-0311
    hmitchell@sontra.com
SOURCE Sontra Medical Corporation
http://www.sontra.com/
CONTACT:
Harry G. Mitchell, CFO of Sontra Medical
Corporation, +1-508-530-0311, hmitchell@sontra.com